Overview

Contrast-Enhanced Ultrasound Imaging Scan for the Detection of Sentinel Lymph Nodes in Patients With Cervical, Vaginal, or Vulvar Cancer

Status:
Not yet recruiting
Trial end date:
2022-12-21
Target enrollment:
Participant gender:
Summary
This clinical trial compares the use of ultrasound for the detection of sentinel lymph nodes (SLNs) to the standard of care (which varies depending on cancer treatment). The ultrasound contrast agent is called Sonazoid and it consists of tiny gas-filled bubbles about the side of red blood cells. Diagnostic procedures, such as ultrasound with Sonazoid, may help identify more SLNs than standard of care in patients with cervical, vaginal, or vulvar cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
Thomas Jefferson University